Protocol Ledger

NCT07091630 · Phase III · RECRUITING

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Interventional Phase III clinical trial protocol NCT07091630 sponsored by argenx in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-16 Enrollment: 160 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07091630
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)160 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07091630
Protocol FieldVerified Registry Value
NCT IdentifierNCT07091630
Consolidated Lead Sponsorargenx
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment160 participants (ESTIMATED)
Registered Start Date2025-09-16
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI